Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50920 |
Name | tonsil squamous cell carcinoma |
Definition | A tonsil cancer that has_material_basis_in squamous cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer pharynx cancer oropharynx cancer tonsil cancer tonsil squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA R88Q | Alpelisib + Tipifarnib | tonsil squamous cell carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03799445 | Phase II | Ipilimumab + Nivolumab | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03829722 | Phase II | Carboplatin + Nivolumab + Paclitaxel | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | Completed | USA | 0 |
NCT03952585 | Phase II | Nivolumab Cisplatin | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04116047 | Phase III | Cisplatin Cisplatin + Durvalumab | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) (CompARE) | Active, not recruiting | IRL | GBR | 0 |
NCT05879484 | Phase Ib/II | DS-3201b + Pembrolizumab | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS | Not yet recruiting | USA | 0 |